MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 317386 | Name: Cefepime HCl hydrate
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Cefepime is a fourth-generation cephalosporin antibiotic. Cefepime has an extended spectrum of activity against Gram-positive and Gram-negative bacteria, with greater activity against both types of organism than third-generation agents. Cefepime is a broad-spectrum cephalosporin antibiotic and has been used to treat bacteria responsible for causing pneumonia and infections of the skin and urinary tract. Some of these bacteria include Pseudomonas, Escherichia, and Streptococcus species.

Chemical Structure

Cefepime HCl hydrate
CAS#123171-59-5 (2HCl hydrate)

Theoretical Analysis

MedKoo Cat#: 317386

Name: Cefepime HCl hydrate

CAS#: 123171-59-5 (2HCl hydrate)

Chemical Formula: C19H27Cl2N6O5S2+

Exact Mass: 0.0000

Molecular Weight: 554.49

Elemental Analysis: C, 41.16; H, 4.91; Cl, 12.79; N, 15.16; O, 14.43; S, 11.57

Price and Availability

Size Price Availability Quantity
1g USD 350.00 2 Weeks
2g USD 550.00 2 Weeks
5g USD 950.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
103296-32-8 (compound E) 123171-59-5 (2HCl hydrate) 88040-23-7 (free base) 107648-78-2 (sulfate) 107648-80-6 (2HCl)
Synonym
Cefepime Hydrochloride; Cefepime HCl; Cefepime dihydrochloride monohydrate; Quadrocef; Elan.
IUPAC/Chemical Name
1-[[(6R,7R)-7-[[(2Z)-2-(2-amino-4-thiazolyl)-2-(methoxyimino)acetyl]amino]-2-carboxy-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]methyl]-1-methyl-pyrrolidinium, monochloride, monohydrochloride, monohydrate
InChi Key
LRAJHPGSGBRUJN-OMIVUECESA-N
InChi Code
InChI=1S/C19H24N6O5S2.2ClH.H2O/c1-25(5-3-4-6-25)7-10-8-31-17-13(16(27)24(17)14(10)18(28)29)22-15(26)12(23-30-2)11-9-32-19(20)21-11;;;/h9,13,17H,3-8H2,1-2H3,(H3-,20,21,22,26,28,29);2*1H;1H2/b23-12-;;;/t13-,17-;;;/m1.../s1
SMILES Code
O=C(O)C1=C(C[N+]2(C)CCCC2)CS[C@@]([C@@H]3NC(/C(C4=CSC(N)=N4)=N\OC)=O)([H])N1C3=O.[Cl-].Cl.O
Appearance
Solid powder
Purity
>97% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO, not in water
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Product Data
Product Data
Instruction
View handling instruction
Biological target:
Cefepime is a broad-spectrum cephalosporin with enhanced coverage against Gram-positive and Gram-negative bacteria.
In vitro activity:
Cefepime is an extended-spectrum parenteral cephalosporin antibiotic active in vitro against a broad spectrum of gram-positive and gram-negative aerobic bacteria. Cefepime has a decreased propensity to induce beta-lactamases compared with other beta-lactam antibiotics. Reference: Am J Med. 1996 Jun 24;100(6A):68S-75S. https://linkinghub.elsevier.com/retrieve/pii/S0002-9343(96)00110-6
In vivo activity:
Cefepime has a pharmacokinetic disposition similar to that of other renally eliminated cephalosporins, with a half-life of approximately 2 hours. Cefepime has demonstrated clinical efficacy against a variety of infections, including urinary tract infections, pneumonia, and skin and skin structure infections. Cefepime is generally well tolerated Reference: Ann Pharmacother. 1996 Dec;30(12):1414-24. https://journals.sagepub.com/doi/10.1177/106002809603001211?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed
Solvent mg/mL mM comments
Solubility
DMSO 6.0 10.50
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 554.49 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
1. Neu HC. Safety of cefepime: a new extended-spectrum parenteral cephalosporin. Am J Med. 1996 Jun 24;100(6A):68S-75S. doi: 10.1016/s0002-9343(96)00110-6. PMID: 8678100.
In vivo protocol:
1. Wynd MA, Paladino JA. Cefepime: a fourth-generation parenteral cephalosporin. Ann Pharmacother. 1996 Dec;30(12):1414-24. doi: 10.1177/106002809603001211. PMID: 8968455.
1: Ajibola O, Aremu TO, Dada SO, Ajibola O, Adeyinka KO, Ajibola A, Oluwole OE. The Trend of Cefepime-Induced Neurotoxicity: A Systematic Review. Cureus. 2023 Jun 26;15(6):e40980. doi: 10.7759/cureus.40980. PMID: 37503476; PMCID: PMC10370502. 2: Jean-Michel V, Homey C, Devos P, Delannoy PY, Boussekey N, Caulier T, Leroy O, Georges H. Continuous Infusion of High Doses of Cefepime in Intensive Care Unit: Assessment of Steady-State Plasma Level and Incidence on Neurotoxicity. Antibiotics (Basel). 2022 Dec 30;12(1):69. doi: 10.3390/antibiotics12010069. PMID: 36671270; PMCID: PMC9854724. 3: Al Kamaly O. Review on Characterization, Properties, and Analytical Methods of Cefepime. Int J Anal Chem. 2022 Jun 29;2022:6909528. doi: 10.1155/2022/6909528. PMID: 35814263; PMCID: PMC9259364. 4: Pais GM, Chang J, Barreto EF, Stitt G, Downes KJ, Alshaer MH, Lesnicki E, Panchal V, Bruzzone M, Bumanglag AV, Burke SN, Scheetz MH. Clinical Pharmacokinetics and Pharmacodynamics of Cefepime. Clin Pharmacokinet. 2022 Jul;61(7):929-953. doi: 10.1007/s40262-022-01137-y. Epub 2022 Jun 29. PMID: 35764774; PMCID: PMC9345683. 5: Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. Cefepime. 2022 Apr 18. PMID: 30000393. 6: Nguyen DD, Lai S. Prolonged Cefepime-Induced Neurotoxicity in a Patient with End-Stage Renal Disease. Am J Case Rep. 2022 Jan 24;23:e934083. doi: 10.12659/AJCR.934083. PMID: 35067669; PMCID: PMC8800466. 7: Su CY, Lin WH. Cefepime Induced Neurotoxicity Mimicking Clinical Presentation of Left Middle Cerebral Artery Infarction: A Case Report and Review of Literature. Acta Neurol Taiwan. 2022 Jan 25;31(1):41-45. PMID: 34988953. 8: Muradbegovic J, Leidi A, Serratrice J. Encéphalopathie au céfépime [Cefepime- induced encephalopathy]. Rev Med Suisse. 2019 Nov 27;15(673):2210-2212. French. PMID: 31778052. 9: McDonald D, Shah P. Cefepime Dosing in Neonates: What is the Evidence? Am J Perinatol. 2021 Jun;38(7):657-661. doi: 10.1055/s-0039-3400312. Epub 2019 Nov 27. PMID: 31777048. 10: Bechashk SM, Moradi G, Mohsenpour B, Ramazanzadeh R. Prevalence of Cefepime- Resistant Escherichia coli in Iran: A Meta-Analysis (2007-2016). Iran J Public Health. 2019 Apr;48(4):603-611. PMID: 31110970; PMCID: PMC6500536. 11: Patel HB, Lusk KA, Cota JM. The Role of Cefepime in the Treatment of Extended-Spectrum Beta-Lactamase Infections. J Pharm Pract. 2019 Aug;32(4):458-463. doi: 10.1177/0897190017743134. Epub 2017 Nov 22. PMID: 29166830. 12: Payne LE, Gagnon DJ, Riker RR, Seder DB, Glisic EK, Morris JG, Fraser GL. Cefepime-induced neurotoxicity: a systematic review. Crit Care. 2017 Nov 14;21(1):276. doi: 10.1186/s13054-017-1856-1. PMID: 29137682; PMCID: PMC5686900. 13: Appa AA, Jain R, Rakita RM, Hakimian S, Pottinger PS. Characterizing Cefepime Neurotoxicity: A Systematic Review. Open Forum Infect Dis. 2017 Oct 10;4(4):ofx170. doi: 10.1093/ofid/ofx170. PMID: 29071284; PMCID: PMC5639733. 14: Toda Y, Yamazaki M, Ota T, Fujisawa Y, Kimura K. [A case of Cefepime encephalopathy, being difficult to distinguish from non-convulsive status epilepticus during the treatment of bacterial meningitis]. Rinsho Shinkeigaku. 2016 Oct 28;56(10):678-683. Japanese. doi: 10.5692/clinicalneurol.cn-000898. Epub 2016 Oct 28. Erratum in: Rinsho Shinkeigaku. 2016;56(11):788. PMID: 27680224. 15: Lindsay H, Gruner S, Brackett J. Cefepime-Induced Neurotoxicity Despite Dose Adjustment for Renal Disease: A Brief Report and Review of the Literature. J Pediatric Infect Dis Soc. 2017 Jun 1;6(2):199-201. doi: 10.1093/jpids/piw022. PMID: 27147713. 16: Burgess SV, Mabasa VH, Chow I, Ensom MH. Evaluating outcomes of alternative dosing strategies for cefepime: a qualitative systematic review. Ann Pharmacother. 2015 Mar;49(3):311-22. doi: 10.1177/1060028014564179. Epub 2015 Jan 9. PMID: 25575975. 17: Mani LY, Kissling S, Viceic D, Vogt B, Burnier M, Buclin T, Renard D. Intermittent hemodialysis treatment in cefepime-induced neurotoxicity: case report, pharmacokinetic modeling, and review of the literature. Hemodial Int. 2015 Apr;19(2):333-43. doi: 10.1111/hdi.12198. Epub 2014 Jul 23. PMID: 25052578. 18: Nguyen HM, Shier KL, Graber CJ. Determining a clinical framework for use of cefepime and β-lactam/β-lactamase inhibitors in the treatment of infections caused by extended-spectrum-β-lactamase-producing Enterobacteriaceae. J Antimicrob Chemother. 2014 Apr;69(4):871-80. doi: 10.1093/jac/dkt450. Epub 2013 Nov 20. PMID: 24265230. 19: Adderson EE, Flynn PM, Hoffman JM. Efficacy and safety of cefepime in pediatric patients: a systematic review and meta-analysis. J Pediatr. 2010 Sep;157(3):490-5, 495.e1. doi: 10.1016/j.jpeds.2010.03.023. PMID: 20434167. 20: Bazan JA, Martin SI, Kaye KM. Newer beta-lactam antibiotics: doripenem, ceftobiprole, ceftaroline, and cefepime. Infect Dis Clin North Am. 2009 Dec;23(4):983-96, ix. doi: 10.1016/j.idc.2009.06.007. PMID: 19909894.